Adjuvant treatment with pegylated interferon alpha-2a versus low-dose interferon alpha-2a in patients with high-risk melanoma. A randomized phase III DeCOG trial

Pegylated-Interferon-alpha did not improve the outcome over low dose Interferon-alpha in the adjuvant treatment of intermediate and high risk melanoma patients. A higher percentage of patients under Pegylated-Interferon-alpha discontinued treatment due to toxicity.

from Cancer via ola Kala on Inoreader http://ift.tt/1Ursk7o
via IFTTT